Effects of Adrenal Artery Ablation and Adrenalectomy in Patients With Primary Aldosteronism

An Parallel Control Clinical Trail on Effects of Adrenal Artery Ablation and Adrenalectomy in Patients With Primary Aldosteronism

Primary aldosteronism (PA) is the main cause of secondary hypertension, affecting 5-15% of the general hypertensive population. Early diagnosis and treatment are of crucial importance as patients with PA are more susceptible to cardiovascular and cerebrovascular morbidity and mortality than blood-pressure-matched hypertensive patients.

Current guidelines indicate that mineralocorticoid receptor (MR) antagonists and laparoscopic adrenalectomy are the principal treatments for PA.Laparoscopic adrenalectomy is recommended for patients with aldosteronoma or unilateral adrenal hyperplasia. During the past two decades, catheter-based arterial embolization or computed tomography (CT)-guided radiofrequency thermogenesis have been used for aldosteronomas treatment. Although these procedures are claimed to be effective for treatment of aldosteronomas, the evidence comes mostly from case reports or small series. In addition, some PA patients refuse surgery and are intolerant of the adverse effects of MR antagonists; others have persistence of PA after adrenelectomy, but respond poorly to MR antagonists. An alternative therapy is needed in such cases.

In recent years, adrenal artery ablation has also been used to treat primary aldosteronism, which can reduce the level of aldosterone and blood pressure, but its efficacy and safety are not clear. To confirm the effect of adrenal artery ablation on blood pressure, RAAS system and blood potassium, the researchers conducted a parallel control clinical study of patients with primary aldosteronism (Aldosteronoma).

Study Overview

• Status: Completed
• Conditions: Hypertension; Primary Aldosteronism
• Intervention / Treatment: Procedure: Endovascular chemical ablation of adrenal gland

• Study Type: Observational
• Enrollment (Actual): 110
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Chongqing
    • Chongqing, Chongqing, China, 400042
      • The third hospital affiliated to the Army Medical University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Chinese

Description

Inclusion Criteria:

• Primary aldosteronis diagnosed by increased aldosterone-to-renin ratio (ARR) and serum aldosterone levels ≥15 ng / dl, and confirmed by saline injection test or captopril inhibition test.
• Aldosteronoma had lateralization by adrenal venous sampling (AVS) and confirmed with CT
• Signed informed consent and agreed to participate in this study.

Exclusion Criteria:

• Aldosterone cancer.
• Hyperkalemia.
• Renal failure or the following history of nephropathy: serum creatinine 1.5 times higher than the upper limit; dialysis history; or nephrotic syndrome.
• Secondary hypertension except the primary aldosteronism.
• Adrenergic insufficiency.
• Heart failure with NYHA Ⅱ-Ⅳ grade or unstable angina, severe cardiovascular and cerebrovascular stenosis, myocardial infarction, intracranial aneurysm, stroke and other acute cardiovascular events.
• Acute infections, tumors and severe arrhythmias, psychiatric disorders, drugs or alcohol addicts.
• Liver dysfunction or the following history of liver disease: AST or ALT 2 times higher than the upper limit, liver cirrhosis, history of hepatic encephalopathy, esophageal variceal history or portal shunt history.
• Coagulation dysfunction.
• Pregnant women or lactating women.
• Participated in other clinical trials or admitted with other research drugs within 3 months prior to the trial.
• Allergy or any contraindications for contrast agents and alcohol.
• Refused to sign informed consent

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Adrenal Artery Ablation; Patients in the intervention group will be treated with ablation of adrenal gland by endovascular injection of dehydrated alcohol	Procedure: Endovascular chemical ablation of adrenal gland; Patients in this group will be treated with ablation of adrenal gland by endovascular injection of dehydrated alcohol
Adrenalectomy; Patients in this group will be treated with unilateral laparoscopic adrenalectomy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of office systolic and diastolic pressure	Change of office systolic and diastolic pressure between the intervention and control group at the end of the study (24 weeks)	52 weeks (End of Trial)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of 24-h average systolic blood pressure	Change of 24-h average systolic blood pressure between the intervention and control group at the end of the study (24 weeks)	52 weeks (End of Trial)
Change of 24-h average diastolic blood pressure	Change of 24-h average diastolic blood pressure, daytime mean systolic blood pressure, daytime mean diastolic blood pressure, and nighttime average systolic and diastolic blood pressure between the intervention and control group at the end of the study (24 weeks)	52 weeks (End of Trial)
Change of home systolic and diastolic pressure	Change of home systolic and diastolic pressure between the intervention and control group at the end of the study (24 weeks)	52 weeks (End of Trial)
Change of anti-hypertensive regimen	Change of number, classes, and combinations of classes of antihypertensive drugs between the intervention and control group at the end of the study (24 weeks)	52 weeks (End of Trial)
Change of blood electrolytes（serum potassium and natrium in mmol/L）	Change of blood electrolytes（serum potassium and natrium in mmol/L）compared with baseline, and between the intervention and control group at the end of the study (24 weeks)between the intervention and control group at the end of the study (24 weeks)	52 weeks (End of Trial)
Change of aldosterone-to-renin ratio (ARR）	Change of aldosterone-to-renin ratio (ARR）compared with baseline, and between the intervention and control group at the end of the study (24 weeks)	52 weeks (End of Trial)
Change of plasma aldosterone	Change of plasma aldosterone compared with baseline, and between the intervention and control group at the end of the study (24 weeks)	52 weeks (End of Trial)
Change of plasma renin	Change of plasma renin compared with baseline, and between the intervention and control group at the end of the study (24 weeks)	52 weeks (End of Trial)
Change of plasma cortisol	Change of plasma cortisol compared with baseline, and between the intervention and control group at the end of the study (24 weeks)	52 weeks (End of Trial)
Change of serum creatinine	Change of serum creatinine compared with baseline, and between the intervention and control group at the end of the study (24 weeks)	52 weeks (End of Trial)
Change of estimated glomerular filtration rate(eGFR)	Change of estimated glomerular filtration rate(eGFR) compared with baseline, and between the intervention and control group at the end of the study (24 weeks)	52 weeks (End of Trial)
Change of 24-h urine microalbumin, microalbumin/creatinine ratio	Change of 24-h urine microalbumin, microalbumin/creatinine ratio compared with baseline, and between the intervention and control group at the end of the study (24 weeks)	52 weeks (End of Trial)

Collaborators and Investigators

• Sponsor: Third Military Medical University

Study record dates

Study Major Dates

• Study Start (Actual): January 19, 2016
• Primary Completion (Actual): December 30, 2019
• Study Completion (Actual): June 1, 2021

Study Registration Dates

• First Submitted: February 12, 2020
• First Submitted That Met QC Criteria: February 12, 2020
• First Posted (Actual): February 17, 2020

Study Record Updates

• Last Update Posted (Actual): March 22, 2024
• Last Update Submitted That Met QC Criteria: March 20, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: Hypertension; Primary Aldosteronism; Adrenalectomy; Adrenal Artery Ablation
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Endocrine System Diseases; Adrenocortical Hyperfunction; Adrenal Gland Diseases; Hypertension; Hyperaldosteronism; Physiological Effects of Drugs; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Adrenergic alpha-Agonists; Adrenergic Agonists; Bronchodilator Agents; Anti-Asthmatic Agents; Respiratory System Agents; Adrenergic beta-Agonists; Sympathomimetics; Vasoconstrictor Agents; Mydriatics; Epinephrine; Racepinephrine; Epinephryl borate
• Other Study ID Numbers: Quadruple A -PA

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No